#Paris #France #Rare Diseases #Norgine #Theravia

Norgine Completes Acquisition of Theravia

Norgine, a prominent pharmaceutical company, has successfully completed its acquisition of Theravia, a specialized international firm focused on therapies designed for patients grappling with rare and debilitating diseases. This strategic move marks a significant advancement for Norgine in its mission to provide life-changing medications to individuals with considerable unmet medical needs.

The acquisition, finalized from Norgine's headquarters in Paris, signifies a major step forward in broadening its product offerings in the rare diseases sector.

Integration and Future Goals

Following the official closure of the acquisition, Norgine is set to implement a structured integration process. This will ensure that operations, systems, and teams align seamlessly within the organization, reinforcing Norgine’s robust operational capabilities. Janneke van der Kamp, CEO of Norgine, expressed enthusiasm about the acquisition and its implications for the company's strategic growth. She stated, “We are delighted to close this acquisition, as bringing Theravia into our family strengthens our expertise in rare diseases.”

The focus on integrating Theravia will also enable Norgine to broaden its outreach in regions with significant medical needs, particularly in Europe, Australia, and New Zealand, ensuring that the innovative treatments developed by Theravia reach the patients who need them the most.

Norgine's Commitment to Patient Care

Norgine's commitment isn't just about expanding its portfolio; it’s about enhancing patient care. The integration of Theravia will empower Norgine to maintain its high standard of delivering transformative healthcare solutions to more than 25 million patients annually. The company boasts over 120 years in the industry and has accumulated revenues exceeding €550 million, which speaks to both its longevity and dedication to improving lives through health care initiatives.

Norgine's integrated approach combines strong commercial capabilities with deep medical, regulatory, and clinical expertise, comprehensive internal manufacturing, and robust supply networks. This multifaceted strategy enables the company to deliver high-quality, life-changing medications swiftly and efficiently.

Looking Ahead

As Norgine continues to evolve, the incorporation of Theravia signals a commitment to innovation in healthcare. It places Norgine in a prime position to lead efforts in therapeutics, particularly within the nuanced and challenging domain of rare diseases.

With the integration underway, Norgine aims to uphold its legacy of excellence while pushing the boundaries of medical innovation. This acquisition not only aligns with Norgine’s historical emphasis on patient-centered care but also sets the stage for future endeavors that will redefine how rare diseases are treated.

For media inquiries regarding this acquisition and further information on Norgine's ongoing projects, Annabel Cowper from Norgine can be contacted directly at [email protected]